<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998436</url>
  </required_header>
  <id_info>
    <org_study_id>NG-A16</org_study_id>
    <nct_id>NCT03998436</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novalead Pharma Private Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novalead Pharma Private Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current Study is to determine the safety and effectiveness of Galnobax®&#xD;
      plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU).&#xD;
      In addition, Study is designed to investigate the safety of Galnobax® vehicle for&#xD;
      establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU.&#xD;
      The study is being conducted in 350 subjects being recruited in about 30 centers in India.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is a Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to&#xD;
      Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in&#xD;
      Treating Diabetic Foot Ulcers. The study evaluates the safety and effectiveness of Galnobax®&#xD;
      plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU).&#xD;
      In addition, Study is designed to investigate the safety of Galnobax® vehicle for&#xD;
      establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, Multicenter, Randomized, Double-Blind, Parallel groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The subject will be masked from the treatment by the Study Nurse (care giver) by using blinder during each treatment application. The site has two separate teams (blinded and unblinded) for masking. The unblinded investigator performs application of treatment during each treatment visit of subject to the site.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects achieving Target Ulcer Closure within 12-week Treatment Phase, as assessed by blinded Investigator</measure>
    <time_frame>12-weeks</time_frame>
    <description>Primary efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Target Ulcer Closure during the 12-week Treatment Phase, as assessed by the blinded Investigator.</measure>
    <time_frame>12-weeks</time_frame>
    <description>Secondary efficacy endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects achieving Target Ulcer Closure till End of Study, as assessed by the blinded Investigator.</measure>
    <time_frame>24-weeks</time_frame>
    <description>Secondary efficacy endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Subjects with treatment emergent adverse events (TEAEs)</measure>
    <time_frame>24-weeks</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects with events related to the local wound assessment of Target Ulcer in Vehicle plus Standard of Care group.</measure>
    <time_frame>24-weeks</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Galnobax® 14% gel plus SoC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC Only</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Only Standard of Care will be administered twice daily (150 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle plus SoC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol Hydrochloride</intervention_name>
    <description>Galnobax-14% gel application along with Standard of Care</description>
    <arm_group_label>Galnobax® 14% gel plus SoC</arm_group_label>
    <other_name>Galnobax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Only Standard of Care</intervention_name>
    <description>Only Standard of Care treatment</description>
    <arm_group_label>SoC Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Vehicle gel application along with Standard of Care</description>
    <arm_group_label>Vehicle plus SoC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects, male or female, aged 18 to 75 years (inclusive) with Type 1 or Type 2&#xD;
             diabetes undergoing therapy for glycemic control&#xD;
&#xD;
          2. Subject has glycosylated hemoglobin, HbA1C, ≤ 12%&#xD;
&#xD;
          3. Subject with diagnosis of neuropathic foot ulcer by 10g monofilament test&#xD;
&#xD;
          4. Subject has adequate vascular perfusion of the affected limb, confirmed by&#xD;
             Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.3&#xD;
&#xD;
          5. Presence of at least one DFU that meets all of the following criteria:&#xD;
&#xD;
               1. A full-thickness ulcer of Grade A1 as per Texas classification system;&#xD;
&#xD;
               2. Ulcer is located below or up to 5 cm above the malleoli (excluding ulcers between&#xD;
                  the toes);&#xD;
&#xD;
               3. Ulcer size (area) is ≥ 2 cm2 and ≤ 15 cm2 (post-debridement);&#xD;
&#xD;
               4. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other&#xD;
                  ulcers on the specified foot, post-debridement;&#xD;
&#xD;
               5. No exposed bone, tendon, muscle, ligament or joint capsule, and no tunneling,&#xD;
                  undermining, or sinus tracts;&#xD;
&#xD;
               6. Unresponsive to ulcer care and open for at least 6 weeks at the time of the&#xD;
                  Screening Visit;&#xD;
&#xD;
               7. Ulcer is non-infected as determined by clinical assessment and complete hemogram;&#xD;
&#xD;
               8. Ulcer has a clean, granulating base free of adherent slough to the greatest&#xD;
                  extent possible as per Investigator;&#xD;
&#xD;
               9. Ulcer area reduction &lt; 30% from the Screening Visit to Baseline visit&#xD;
&#xD;
          6. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered&#xD;
             not clinically significant by the Investigator&#xD;
&#xD;
          7. Subject, if female of child-bearing potential, has a negative urine pregnancy test at&#xD;
             Screening and willing to use acceptable methods of contraception (birth control pills,&#xD;
             barriers) or abstinence throughout the Study&#xD;
&#xD;
          8. Subject is able and willing to comply with Study procedures including the use of an&#xD;
             off-loading device (as applicable for the location of the ulcer) and adhere to&#xD;
             protocol during the Study in the opinion of Investigator&#xD;
&#xD;
          9. A Subject or LAR agrees to sign informed consent form and allow audio visual recording&#xD;
             of consent, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Actively infected ulcers with or without purulent discharge, ulcers with exposed bone&#xD;
             or associated with osteomyelitis&#xD;
&#xD;
          2. Subjects with more than three ulcers below knee&#xD;
&#xD;
          3. Subjects with Target Ulcer requiring off-loading that cannot be effectively&#xD;
             off-loaded; or unable to tolerate the off-loading method&#xD;
&#xD;
          4. Subject has ulcers caused by a disease other than diabetes, e.g., fungal ulcerations,&#xD;
             malignant ulcerations, and ulcerations due to venous or arterial insufficiency, or due&#xD;
             to hematological disorders, in the opinion of the Investigator&#xD;
&#xD;
          5. Ulcer, about which the Investigator is suspicious for cancer&#xD;
&#xD;
          6. Subjects with a gangrenous or ischemic ulcer&#xD;
&#xD;
          7. Subject with ulcer that in the opinion of the Investigator, may need amputation&#xD;
&#xD;
          8. Subject with Target ulcer where wound measurement is not possible, such as ulcers&#xD;
             between toes&#xD;
&#xD;
          9. Body mass index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
         10. Laboratory values at Screening of:&#xD;
&#xD;
               1. Hemoglobin &lt; 10.0 g/dL&#xD;
&#xD;
               2. White Blood Cells (WBC) &lt; 2.0 X 109 cells/L&#xD;
&#xD;
               3. Liver function studies [Total bilirubin, aspartate aminotransferase (AST) and&#xD;
                  alanine transaminase (ALT)] &gt; 3x the upper limit of normal&#xD;
&#xD;
               4. Albumin &lt; 2.5 g/dL&#xD;
&#xD;
               5. eGFR &lt; 25 mL/min&#xD;
&#xD;
         11. Presence of any existing clinically significant medical condition(s) that, in the&#xD;
             opinion of the Investigator, could interfere with wound healing&#xD;
&#xD;
         12. Subject has received or is currently receiving or scheduled to receive any medication&#xD;
             or therapies during the course of the Study that will modulate wound healing&#xD;
&#xD;
         13. Subject with intolerance to β-blockers at any time in the past&#xD;
&#xD;
         14. Has any other factor which may, in the opinion of the Investigator, compromise&#xD;
             participation and/or follow-up in the Study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>M.S. Ramaiah Medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Desai, MS</last_name>
      <phone>9845290575</phone>
      <email>scdesai@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manisha Deshmukh, MD</last_name>
      <phone>9823129387</phone>
      <email>mandeshmukh@rediffmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chellaram Diabetes Institute</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411021</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A G Unnikrishnan, MD</last_name>
      <phone>9689287337</phone>
      <email>unnikrishnanag@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital for Diabetes Pvt Ltd</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Viswanathan, M.D.</last_name>
      <phone>9840055535</phone>
      <email>drvijay@mvdiabetes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madras Diabetes Research Foundation</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muthu Ramu, F. Diab.</last_name>
      <phone>9840923632</phone>
      <email>tmcramu2000@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sri Ramachandra Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhagar Singh, MD</last_name>
      <phone>9003178899</phone>
      <email>drsingh7071@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <zip>110012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashu Rastogi, MD</last_name>
      <phone>9781001046</phone>
      <email>ashuendo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaja Agrasen Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepak Khandelwal, MD</last_name>
      <phone>9968878561</phone>
      <email>khandelwalaiims@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

